Coronavirus Update: Favipiravir Scores In Phase III Trial

Plus: UK Invests In 'At Risk' Vaccines Manufacturing.

Glenmark's Phase III trial of the antiviral points to efficacy in mild-to-moderate COVID-19, but many physicians in India remain skeptical.  

Curfew
Miami Beach, South Florida. Night time curfews have been introduced to stem the spread of COVID-19, one of the US regions worst hit by the second spike in cases.

Glenmark Pharmaceuticals Limited has unveiled top-line results from its Phase III clinical trial with favipiravir, indicating that early treatment with the antiviral improves clinical outcomes for mild-to-moderate patients and potentially prevent their condition from worsening to acute respiratory distress syndrome or death.

Favipriravir has already received emergency use authorization (EUA) in India for the treatment of mild to moderate COVID-19, where it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip